1. Home
  2. RVMD vs KVUE Comparison

RVMD vs KVUE Comparison

Compare RVMD & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Revolution Medicines Inc.

RVMD

Revolution Medicines Inc.

HOLD

Current Price

$154.30

Market Cap

30.1B

Sector

Health Care

ML Signal

HOLD

Logo Kenvue Inc.

KVUE

Kenvue Inc.

HOLD

Current Price

$17.61

Market Cap

32.9B

ML Signal

HOLD

Company Overview

Basic Information
Metric
RVMD
KVUE
Founded
2014
2022
Country
United States
United States
Employees
883
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Specialty Chemicals
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
30.1B
32.9B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
RVMD
KVUE
Price
$154.30
$17.61
Analyst Decision
Strong Buy
Buy
Analyst Count
19
11
Target Price
$140.84
$19.45
AVG Volume (30 Days)
2.0M
17.5M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
4.82%
EPS Growth
N/A
40.74
EPS
N/A
0.25
Revenue
N/A
$15,124,000,000.00
Revenue This Year
N/A
$4.85
Revenue Next Year
$533.02
$2.63
P/E Ratio
N/A
$70.54
Revenue Growth
N/A
N/A
52 Week Low
$34.00
$14.02
52 Week High
$156.25
$23.78

Technical Indicators

Market Signals
Indicator
RVMD
KVUE
Relative Strength Index (RSI) 62.04 53.57
Support Level $93.39 $17.20
Resistance Level N/A $17.77
Average True Range (ATR) 5.02 0.31
MACD -0.50 0.04
Stochastic Oscillator 81.16 58.69

Price Performance

Historical Comparison
RVMD
KVUE

About RVMD Revolution Medicines Inc.

Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.

About KVUE Kenvue Inc.

Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.

Share on Social Networks: